Skip to content

Traumatic Splenic Injury and Management (SPLENIQ Study)

Traumatic Splenic Injury and Management (SPLENIQ Study) Quality of Life and Clinical Outcomes of Treatment for Splenic Injury After Trauma

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03099798
Acronym
SPLENIQ
Enrollment
106
Registered
2017-04-04
Start date
2017-03-01
Completion date
2020-12-31
Last updated
2022-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Quality of Life, Spleen Injury, Splenic Artery Embolization, Trauma

Brief summary

OBJECTIVE: To determine the quality of life (QOL) and clinical outcome after conservative therapy, embolization (proximal versus distal) or surgery in patients with traumatic splenic injury. Secondary aims: (I) to examine therapy-related complications, (II) to establish the necessity of additional therapies, (III) the assessment of splenic function related to splenic morphology (MR imaging) after embolization and (IV) to find the prognostic factors for failure of non-operative management (NOM) in patients with splenic injuries. Finally, with the acquired data from this study a patient-oriented protocol will be provided for the management of traumatic splenic injury. HYPOTHESIS: The investigators expect that NOM is superior to surgery with regard to QOL, clinical outcome and splenic function. Embolization will need more additional therapies. Splenic morphology is related to splenic immune function. Expected prognostic factors are age above 40, ISS \>25 and a splenic injury grade of 3 or higher. STUDY DESIGN: A combination of a retrospective and a prospective multicentre cohort study. This protocol involves the prospective part of the study. STUDY POPULATION/DATASET: Patients who enter the participating hospitals between March 2017 and December 2018 with splenic injury will be asked to participate. The follow-up period will be one year with regard to QOL, clinical symptoms and imaging. INTERVENTION: All patients will complete a number of questionnaires at different time points. The patients who were treated with splenic artery embolization (SAE) will undergo an MRI one month and one year after treatment. OUTCOME MEASURES: Primary outcome is QOL. Secondary outcomes are clinical symptoms and imaging. SAMPLE SIZE: Approximately 100 patients will be included per year during the inclusion phase. DATA ANALYSIS: With regard to the prospective data linear modelling will be performed. COLLABORATION/CONNECTION: Tilburg University, Erasmus Medical Center Rotterdam, Maasstad Hospital Rotterdam, Albert Schweitzer Hospital Dordrecht, Amphia hospital Breda, Leiden University Medical Center, VU University Medical Center Amsterdam, Medical Spectrum Twente, Radboud University Nijmegen, Isala Zwolle. TIME SCHEDULE: Year 1: literature search and conducting the retrospective study and analyses. Years 1-3: inclusion prospective study and follow-up of patients. Year 4: finishing follow-up data collection and analysing.

Interventions

OTHERQuestionnaires

All patients will complete a number of questionnaires at different time points. * SF-12, WHOQoL-Bref, EQ-5D-5L, iPCQ, iMCQ * 1 week, 1 month, 3, 6 and 12 months after treatment

DIAGNOSTIC_TESTMRI abdomen

Patients who were treated with splenic artery embolization will also undergo an MRI one month and one year after treatment.

Sponsors

Erasmus Medical Center
CollaboratorOTHER
Maasstad Hospital
CollaboratorOTHER
Albert Schweitzer Hospital
CollaboratorOTHER
Amphia Hospital
CollaboratorOTHER
Tilburg University
CollaboratorOTHER
Leiden University Medical Center
CollaboratorOTHER
Amsterdam UMC, location VUmc
CollaboratorOTHER
Medisch Spectrum Twente
CollaboratorOTHER
Radboud University Medical Center
CollaboratorOTHER
Isala
CollaboratorOTHER
Elisabeth-TweeSteden Ziekenhuis
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Splenic injury after blunt abdominal trauma (confirmed by FAST and/or CT) * The patient underwent NOM/SAE/splenectomy for the management of traumatic splenic injury * The treatment took place in the period from March 2017 to December 2018 at one of the five selected hospitals * 18 years or older.

Exclusion criteria

* Insufficient knowledge of the Dutch language * Patients who died during or after treatment are (of course) excluded for questionnaires and MRI, not for clinical outcomes Exclusion for MRI only: \- Patients treated with SAE: patients who do not want to or are not able to undergo an MRI abdomen (for example pregnant women or other contraindications for MRI). Patients excluded for MRI still need to fill out the questionnaires. Also, their clinical outcomes will be processed in the database.

Design outcomes

Primary

MeasureTime frameDescription
Change in health related quality of life: EQ-5D-5LOne week, 1 month and 3, 6 and 12 months after treatmentEQ-5D-5L questionnaire
Quality of life: 1 month follow-upOne month after treatmentWHOQoL-Bref questionnaire
Quality of life: 3 months follow-upThree months after treatmentWHOQoL-Bref questionnaire
Quality of Life: baseline (within 1 week after treatment)One week after treatmentWHOQoL-Bref questionnaire, SF-12 and EQ-5D-5L questionnaires
Quality of life: 6 months follow-upSix months after treatmentWHOQoL-Bref questionnaire
Quality of life: one year follow-upOne year after treatmentWHOQoL-Bref questionnaire
Change in health status: SF-12One week, 1 month and 3, 6 and 12 months after treatmentSF-12 questionnaire

Secondary

MeasureTime frameDescription
Cost-effectivenessOne year follow-upThe overall cost-effectiveness will be assessed with the iPCQ and iMCQ questionnaires, completed at different time points
Imaging Outcome after Embolization (one month after treatment)One month after embolizationSplenic morphological characteristics (e.g. volume, necrosis, splenosis, calcifications or chronic infarction morphology)
Imaging Outcome after Embolization (one year after treatment)One year after embolizationSplenic morphological characteristics (e.g.volume, necrosis, splenosis, calcifications or chronic infarction morphology)
Splenic Artery Embolization characteristicsOne year follow-upDifference between proximal versus distal embolization
Prognostic factors for failure of Non-Operative ManagementOne year follow-upA recent study suggests that there are prognostic factors for failure of NOM in the treatment of adults with (blunt) splenic injury. Strong evidence exists for: age of 40 years or above, Injury Severity Score (ISS) of 25 or greater and American Association for the Surgery of Trauma (AAST) splenic injury grade of 3 or greater.
Clinical OutcomeOne year follow-upData obtained from the patient records (e.g. complications, need for re-intervention, hospital stay, return to daily activities)

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 3, 2026